TW200722088A - Diabetes remedy - Google Patents

Diabetes remedy

Info

Publication number: TW200722088A
Authority: TW; Taiwan
Prior art keywords: diabetes; diabetes remedy; benzoimidazol; methy1; ylmethoxy
Prior art date: 2005-05-27

Application number

TW095118747A

Other languages

English (en)

Inventor

Ryutaro Nakashima

Junko Ogawa

Akira Okuno

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-27

Filing date

2006-05-26

Publication date

2007-06-16

2006-05-26 Application filed by Sankyo Co filed Critical Sankyo Co

2007-06-16 Publication of TW200722088A publication Critical patent/TW200722088A/zh

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW095118747A 2005-05-27 2006-05-26 Diabetes remedy TW200722088A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2005155174		2005-05-27

Publications (1)

Publication Number	Publication Date
TW200722088A true TW200722088A (en)	2007-06-16

Family

ID=37452094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095118747A TW200722088A (en)	2005-05-27	2006-05-26	Diabetes remedy

Country Status (5)

Country	Link
US (1)	US20090227493A1 (zh)
EP (1)	EP1889618A4 (zh)
JP (1)	JPWO2006126673A1 (zh)
TW (1)	TW200722088A (zh)
WO (1)	WO2006126673A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8722710B2 (en)	2007-09-26	2014-05-13	Deuterx, Llc	Deuterium-enriched pioglitazone
WO2009158704A2 (en)	2008-06-27	2009-12-30	Duke University	Therapeutic agents comprising elastin-like peptides
CN102321170B (zh) *	2011-09-14	2013-11-13	深圳翰宇药业股份有限公司	利拉鲁肽变构体及其缀合物
AU2014236510A1 (en)	2013-03-14	2015-09-24	Deuterx, Llc	Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
EP3666273A3 (en)	2014-01-15	2020-10-28	Poxel SA	Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10934279B2 (en)	2018-06-13	2021-03-02	Pfizer Inc.	GLP-1 receptor agonists and uses thereof
US11319313B2 (en)	2020-06-30	2022-05-03	Poxel Sa	Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en)	2020-06-30	2023-09-26	Poxel Sa	Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04504246A (ja) *	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン刺激ホルモン
CA2073856C (en) *	1990-01-24	2002-12-03	Douglas I. Buckley	Glp-1 analogs useful for diabetes treatment
CZ293016B6 (cs) *	1995-06-01	2004-01-14	Sankyo Company Limited	Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
CZ300837B6 (cs) *	1996-08-30	2009-08-26	Novo Nordisk A/S	Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
WO2000038666A2 (en) *	1998-12-24	2000-07-06	Metabasis Therapeutics, Inc.	A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
DK1140145T4 (da) *	1999-01-14	2019-07-22	Amylin Pharmaceuticals Llc	Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
TWI284533B (en) *	1999-05-24	2007-08-01	Sankyo Co	Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
US6586438B2 (en) *	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
WO2003002136A2 (en) *	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
WO2006127948A2 (en) *	2005-05-26	2006-11-30	Bristol-Myers Squibb Company	N-terminally modified glp-1 receptor modulators

2006
- 2006-05-26 US US11/915,734 patent/US20090227493A1/en not_active Abandoned
- 2006-05-26 JP JP2007517914A patent/JPWO2006126673A1/ja not_active Withdrawn
- 2006-05-26 TW TW095118747A patent/TW200722088A/zh unknown
- 2006-05-26 WO PCT/JP2006/310550 patent/WO2006126673A1/ja not_active Ceased
- 2006-05-26 EP EP06746879A patent/EP1889618A4/en not_active Withdrawn

Also Published As

Publication number	Publication date
JPWO2006126673A1 (ja)	2008-12-25
EP1889618A1 (en)	2008-02-20
EP1889618A4 (en)	2010-11-24
WO2006126673A1 (ja)	2006-11-30
US20090227493A1 (en)	2009-09-10

Similar Documents

Publication	Publication Date	Title
WO2007111864A3 (en)	2008-10-02	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en)	2008-01-10	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TN2009000111A1 (en)	2010-08-19	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20076418L (no)	2008-03-25	Heterocyclic compounds as agonists for the thyroid receptor
MX2009003038A (es)	2009-04-15	Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
WO2007003961A3 (en)	2007-03-01	Gpcr agonists
ECSP088239A (es)	2008-04-28	Composición de liberación de fármaco sostenida
DK1143989T3 (da)	2007-04-16	Exendiner til glucagonundertrykkelse
ATE468332T1 (de)	2010-06-15	Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
CL2007002197A1 (es)	2008-02-15	Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
NZ595314A (en)	2013-03-28	PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
WO2007008752A3 (en)	2007-04-26	Sustained release pharmaceutical compositions for highly water soluble drugs
WO2006015943A3 (en)	2007-02-08	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1894567A4 (en)	2009-05-20	Concomitant pharmaceutical agents and use thereof
IL180916A0 (en)	2007-07-04	Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
CL2011002697A1 (es)	2012-06-01	Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
WO2006024275A3 (de)	2006-11-30	Erfindung betreffend glp-1 und exendin
CL2007003272A1 (es)	2008-03-24	Compuestos derivados de pirazol y triazol sustituidos; y composicion farmaceutica, util para el tratamiento de una enfermedad proliferativa celular.
WO2006082523A3 (en)	2006-09-28	Pharmaceutical sustained release composition of metformin
AR065120A1 (es)	2009-05-20	Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
TW200722088A (en)	2007-06-16	Diabetes remedy
GEP20115230B (en)	2011-06-10	Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
EA200702116A1 (ru)	2008-02-28	Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
MY150046A (en)	2013-11-29	Benzothiazoles as ghrelin receptor modulators
WO2006026316A3 (en)	2006-05-26	Prodrug substituted benzoxazoles as estrogenic agents